Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol

• Status: Completed
• Trial end date: 2005-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To show that Irbesartan improves endothelial dysfunction and the procoagulant state which are thought to be the possible mechanisms, inducing a generalized vasculopathy associated with microalbuminuria and vascular events in type II diabetic hypertensive patients

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Atenolol; Irbesartan

Criteria

Inclusion Criteria:

• non insulin dependent type II manifest diabetes with glycosilated HbA1c levels over %6.5-8

• mild to moderate hypertension stage I and stage II according to ESC-ESH 2003 (140-180 mmHg)

Exclusion Criteria:

• congestive heart failure

• azotemia

• insulin dependent diabetes

• liver insufficiency

• pregnancy

• cancer

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.